Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology.
Yoichi NaitoSaori MishimaKiwamu AkagiAtaru IgarashiMasafumi IkedaSusumu OkanoShunsuke KatoTadao TakanoKatsuya TsuchiharaKeita TerashimaHiroshi NishiharaHiroyki NishiyamaEiso HiyamaAkira HirasawaHajime HosoiOsamu MaedaYasushi YatabeWataru OkamotoShigeru OnoHiroaki KajiyamaFumio NagashimaYutaka HatanakaMitsuru MiyachiYasuhiro KoderaTakayuki YoshinoHiroya TaniguchiPublished in: International journal of clinical oncology (2020)
In the NTRK guideline, the committee proposed 15 recommendations for performing NTRK testing properly to select patients who are likely to benefit from tropomyosin receptor kinase inhibitors.